Arimoclomol-CLEAR Gene Activation for Niemann-Pick Type C
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no FDA-approved disease-modifying therapies for Niemann-Pick disease, type C (NPC), a severely debilitating neurodegenerative lysosomal storage disease, and current treatments primarily rely on symptomatic management, necessitating a combination therapy that targets the etiology of NPC.
Innovation Solution
Arimoclomol, an orally bioavailable small molecule, activates Transcription Factor EB (TFE3) and/or TFE3, in combination with miglustat, to increase the nuclear translocation of TFEB and/or TFE3, upregulating the CLEAR network genes, including NPC1, thereby enhancing lysosomal cholesterol removal and NPC1 protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic management is used for NPC, then patient symptoms can be controlled, but disease progression cannot be halted and no disease-modifying effect is achieved
Solution Approach 1:
The patent uses TFEB and TFE3 transcription factors as intermediaries to bridge the gap between available small molecule compounds and the underlying disease mechanism. Arimoclomol and cyclodextrin act as mediators that indirectly modulate CLEAR network gene expression through these transcription factors, achieving disease-modifying effects without directly targeting the mutated NPC1/NPC2 proteins. This intermediary approach enables disease modification using compounds that can be orally administered.
Solution Approach 2:
The patent changes the regulatory parameters of CLEAR network genes (including NPC1) by modulating transcription factor activity rather than directly correcting the genetic mutation. By altering the expression levels of NPC1 through transcriptional regulation via TFEB/TFE3 activation, the patent achieves therapeutic effect with orally available compounds, resolving the contradiction between disease-modifying efficacy and treatment availability.
2Productivity
If CLEAR network genes are upregulated to increase NPC1 protein production, then lysosomal cholesterol removal is enhanced, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent employs preliminary action by using arimoclomol and cyclodextrin to pre-activate TFEB and TFE3 transcription factors before the actual need for increased NPC1 protein synthesis. This upstream activation of transcription factors creates a preparatory state that leads to enhanced CLEAR network gene expression and NPC1 protein production, simplifying the overall treatment approach by targeting an early regulatory step rather than multiple downstream processes.
Solution Approach 2:
The patent utilizes TFEB and TFE3 transcription factors that regulate multiple CLEAR network genes simultaneously, not just NPC1. This multi-functionality allows a single treatment approach to enhance the expression of several lysosomal proteins involved in cholesterol removal, thereby increasing NPC1 production while maintaining a relatively simple treatment mechanism through a universal regulatory pathway.
3Reliability
If combination therapy with arimoclomol and miglustat is used, then disease-modifying effects are achieved, but the treatment protocol becomes more complex
Solution Approach 1:
The patent segments the disease-modifying approach into two distinct but complementary components: arimoclomol/cyclodextrin for upregulating CLEAR network genes and increasing NPC1 expression, and miglustat for inhibiting glucosylceramide synthase and reducing glycosphingolipid accumulation. This segmentation allows each component to target a specific pathological aspect, achieving comprehensive disease modification while maintaining clear, manageable treatment protocols with defined mechanisms for each agent.
Data Source
AI summary
The present disclosure provides methods of treating lysosomal storage disorders such as Niemann-Pick Disease, Type-C, by administering a therapeutically effective amount of arimoclomol in combination with miglustat. The present disclosure further provides methods of removing lysosomal cholesterol by administering the same.